Baxter Q4 Earnings Beat Expectations, Issues Strong 2025 Outlook
1. Baxter Q4 EPS reached 58 cents. Beat guidance and estimates. 2. Sales hit $2.75B. Consensus was $2.67B. 3. Better Medical & Pharma sales drove revenue. Growth exceeded expert guidance. 4. 2025 EPS guidance is optimistic. Q1 EPS guidance slightly lags consensus. 5. Stock surged 8.14% to $33.33. Investor sentiment appears strong.